work the same way as their brand-name counterparts because they have the same active ingredient .
This echoes a pattern from 20 years ago with antiretrovirals for treatment — drug companies would not issue licences, claiming the drugs were too difficult to make, that generics were unreliable, or they were not willing to lower their prices. Viiv Healthcare’s attitude is causing concern, because it is restricting supply for implementation research projects, suggesting it cannot make enough of their product.
If you take PrEP to protect yourself against HIV infection, then that medicine, whether it’s a pill or injection, has to be taken, so that there’s enough of the drug in your body to shield the immune system from infection. , which contains two types of ARVs known as tenofovir and emtricitabine, and is widely available in South Africa in state clinics and in the private sector.With close to 7.6-million South Africans estimated by theto be HIV positive and about 200 000 new HIV infections a year, the country desperately needs PrEP to help slow down new infections.